Literature DB >> 19750041

Alvimopan (Entereg), a Peripherally Acting mu-Opioid Receptor Antagonist For Postoperative Ileus.

Goldina Ikezuagu Erowele.   

Abstract

Entities:  

Year:  2008        PMID： 19750041      PMCID： PMC2730789     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


× No keyword cloud information.
  16 in total

Review 1.  Clinical perspective on postoperative ileus and the effect of opiates.

Authors:  C P Delaney
Journal:  Neurogastroenterol Motil       Date:  2004-10       Impact factor: 3.598

2.  Does metoclopramide reduce the length of ileus after colorectal surgery? A prospective randomized trial.

Authors:  J D Cheape; S D Wexner; K James; D G Jagelman
Journal:  Dis Colon Rectum       Date:  1991-06       Impact factor: 4.585

3.  A double-blind, randomized, placebo-controlled phase III study of the safety of alvimopan in patients who undergo simple total abdominal hysterectomy.

Authors:  Thomas J Herzog; Robert L Coleman; James P Guerrieri; Kathie Gabriel; Wei Du; Lee Techner; John G Fort; Bruce Wallin
Journal:  Am J Obstet Gynecol       Date:  2006-04-19       Impact factor: 8.661

4.  Negative effect of Metoclopramide in postoperative adynamic ileus. A prospective, randomized, double blind study.

Authors:  S Jepsen; A Klaerke; P H Nielsen; O Simonsen
Journal:  Br J Surg       Date:  1986-04       Impact factor: 6.939

5.  Alvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction--a 21-day treatment-randomized clinical trial.

Authors:  Daniel M Paulson; Daniel T Kennedy; Roger A Donovick; Randall L Carpenter; Maryann Cherubini; Lee Techner; Wei Du; Yuju Ma; William K Schmidt; Bruce Wallin; David Jackson
Journal:  J Pain       Date:  2005-03       Impact factor: 5.820

6.  Alvimopan, a peripherally acting mu-opioid receptor antagonist, compared with placebo in postoperative ileus after major abdominal surgery: results of a randomized, double-blind, controlled study.

Authors:  E R Viscusi; S Goldstein; T Witkowski; A Andonakakis; R Jan; K Gabriel; W Du; L Techner; B Wallin
Journal:  Surg Endosc       Date:  2005-12-07       Impact factor: 4.584

7.  Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain.

Authors:  Lynn Webster; Jan Peter Jansen; John Peppin; Ben Lasko; Gordon Irving; Bart Morlion; Jerry Snidow; Amy Pierce; Eric Mortensen; Christi Kleoudis; Eric Carter
Journal:  Pain       Date:  2007-12-31       Impact factor: 6.961

8.  Pharmacokinetics of alvimopan and its metabolite in healthy volunteers and patients in postoperative ileus trials.

Authors:  J F Foss; D M Fisher; V D Schmith
Journal:  Clin Pharmacol Ther       Date:  2007-07-25       Impact factor: 6.875

Review 9.  Emerging pharmacologic options for treating postoperative ileus.

Authors:  Michael D Kraft
Journal:  Am J Health Syst Pharm       Date:  2007-10-15       Impact factor: 2.637

10.  Effect of intravenous erythromycin on postoperative ileus.

Authors:  M Bonacini; S Quiason; M Reynolds; M Gaddis; B Pemberton; O Smith
Journal:  Am J Gastroenterol       Date:  1993-02       Impact factor: 10.864
View more
  7 in total

Review 1.  [Alvimopan for recovery of bowel function after radical cystectomy].

Authors:  Jennifer Kranz; Laura-Maria Krabbe
Journal:  Urologe A       Date:  2018-02       Impact factor: 0.639

2.  Discovery of Axelopran (TD-1211): A Peripherally Restricted μ-Opioid Receptor Antagonist.

Authors:  Daniel D Long; Scott R Armstrong; David T Beattie; Christina B Campbell; Timothy J Church; Pierre-Jean Colson; Sean M Dalziel; John R Jacobsen; Lan Jiang; Glenmar P Obedencio; Miroslav Rapta; Daisuke Saito; Ioanna Stergiades; Pamela R Tsuruda; Priscilla M Van Dyke; Ross G Vickery
Journal:  ACS Med Chem Lett       Date:  2019-11-26       Impact factor: 4.345

Review 3.  Alvimopan for recovery of bowel function after radical cystectomy.

Authors:  Shahnaz Sultan; Bernadette Coles; Philipp Dahm
Journal:  Cochrane Database Syst Rev       Date:  2017-05-02

4.  Efficacy and safety of alvimopan use in benign urinary tract reconstruction.

Authors:  Patrick Hensley; Margaret Higgins; Alison Rasper; Ali Ziada; Stephen Strup; Clyde Coleman; Kathryn Ruf; Shubham Gupta
Journal:  Int Urol Nephrol       Date:  2020-08-31       Impact factor: 2.370

5.  Alvimopan for the Prevention of Postoperative Ileus in Inflammatory Bowel Disease Patients.

Authors:  Janice Jang; Benjamin Kwok; Hua Zhong; Yuhe Xia; Alexis Grucela; Mitchell Bernstein; Feza Remzi; David Hudesman; Jingjing Chen; Jordan Axelrad; Shannon Chang
Journal:  Dig Dis Sci       Date:  2019-09-14       Impact factor: 3.199

Review 6.  Insights into the Use of Peripherally Acting μ-Opioid Receptor Antagonists (PAMORAs) in Oncologic Patients: from Scientific Evidence to Real Clinical Practice.

Authors:  Ana Fernández-Montes; Guillermo de Velasco; Santiago Aguín; Cristina Farriols; María Guirado-Risueño; Vanessa G Jerviz-Guía; María Victoria Baeza-Nadal; Rodolfo Chicas-Sett; José Luis Fírvida; Francisco García-Navalón; Patricia Martín; Carmen Perezagua-Marín; Dulce Rodríguez; Joan Santamaría; Tamara Saurí; Manuel Cobo
Journal:  Curr Treat Options Oncol       Date:  2021-02-26

7.  CIRBP-OGFR axis safeguards against cardiomyocyte apoptosis and cardiotoxicity induced by chemotherapy.

Authors:  Cihang Liu; Xiaolei Cheng; Junyue Xing; Jun Li; Zhen Li; Dongdong Jian; Ying Wang; Shixing Wang; Ran Li; Wanjun Zhang; Dongxing Shao; Xiaohan Ma; Xiru Chen; Jia Shen; Chao Shi; Zhiping Guo; Wengong Wang; Taibing Fan; Lin Liu; Hao Tang
Journal:  Int J Biol Sci       Date:  2022-04-11       Impact factor: 6.580
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.